There are 360 resources available
Welcome and introduction
Presenter: Tullia Bruno
Session: Session in collaboration with SITC: Moving beyond just T cells in the TME
Resources:
Webcast
LBA3 - Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma (NB) Central Nervous System (CNS) and/or Leptomeningeal (LM) Metastases: Updated Results from Pivotal Trial 101
Presenter: Ellen Basu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
No
Presenter: Mark Middleton
Session: Combination of radiotherapy and immunotherapy is a good idea
Resources:
Slides
Webcast
62MO - Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS in Patients with Relapsed or Refractory High-risk Neuroblastoma
Presenter: Jaume Mora
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Second vote and conclusions
Presenter: Jean-Pascal Machiels
Session: Combination of radiotherapy and immunotherapy is a good idea
Resources:
Slides
Webcast
Invited Discussant
Presenter: Ignacio Melero
Session: Mini Oral session 2
Resources:
Slides
Webcast
Panel discussion
Presenter: Sergio Quezada
Session: Session in collaboration with SITC: Moving beyond just T cells in the TME
Resources:
Webcast
LBA1 - Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression
Presenter: Partha Ray
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Conclusions
Presenter: Tullia Bruno
Session: Session in collaboration with SITC: Moving beyond just T cells in the TME
Resources:
Webcast
200MO - Anti-IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: update of initial phase 1 results
Presenter: Matteo Simonelli
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast